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The past half-century has witnessed unbelievable progress in cardiovascular (CV) 
medicine, determining a swirling reduction in mortality. Despite this progress, the decline 
in incidence and mortality leveled off in recent years. Age-adjusted CV mortality remained 
flat independently of race and ethnicity, with only few exceptions. In other words, disparity 
in CV health is still observed across sex, race and ethnicity. The rise of obesity, diabetes 
and other risk factors has been widely used to explain this trend in CV mortality. 
However, inequality in CV health recognizes other determinants. Geographic location, 
wealth and education are associated with different access to basic primary care and 
approach to modifiable CV risk factors 1. As extensively reviewed, they influence 
awareness, treatment and control of dyslipidemia, hypertension, stroke, myocardial 
infarction and childhood obesity among the others.
Noteworthy, this stagnating trend in CV outcome comes together with a progressive rise 
in CV spending, which includes both direct and indirect costs (e.g. loss of work 
productivity, and the need of household assistance). As similar or even better outcomes 
may be reproduced at substantially lower costs in certain context, this raises questions 
about the suitability of CV healthcare spending 2. In light of this, the American Heart 
Association recently recognized six categories of missed opportunities to improve CV 
care and avoid unnecessary costs: i) risk factor modifications; ii) patient engagement and 
involvement; iii) correct diagnosis; iv) adherence and proper use of first-line treatments; 
v) proper use of advance treatments; vi) better use of supportive devices 3. The current 
challenge is then to address the shortfalls of existing treatments, also facing the 
continuous innovations in CV health management. Similar to the European Heart 
Network, also the American Heart Association has recently established the Value in 
Health Care Initiative to increase awareness, access and affordability while eliminating 
barriers to necessary care 3.
However, the planned goals of those initiatives require new forms of CV research, able to 
analyze large amounts of information. Large volumes of data are often available as the 
sample size of CV studies hugely increased along time. While the Framingham Heart 
study started in 1948 with 5,209 patients at first enrollment, the most recent studies are 
enrolling hundreds of thousands of patients and even more than one million patients are 
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main source of “big data” for biomedical research. They merge traditional data (e.g. 
clinical and imaging) with other relevant information from omics, data internet use, 
wearable devices and others 4. As the information increases, their variety also increases. 
Much of the information obtained from HER are unstructured and therefore difficult to 
categorize and analyze. Also considering the time for information creation and storing, 
this remains one of the main challenge in big data analysis 5. Machine/deep learning 
approach integrate and interpret complex biomedical and healthcare data also 
developing automated risk prediction algorithms. CV disease represents a groups of 
diseases that can benefit greatly those algorithms. Their application in prospective clinical 
trials may will have a role for identifying behavioral drivers and therapeutic pathways, 
essential for implementing precision diagnostics, risk stratification and personalized 
therapies.
Other times, data are part of datasets not linked each other. Here, the challenge is to 
remove barriers between data sources by developing specific platforms. Much data 
generated in clinical trials (someone claims up 50%) are kept out, but not at random. 
Positive and statistically significant trials are more likely to be published. Many data from 
clinical trials are often underutilized, whereas third-party scientists could provide an 
independent validation or even provide response to unaddressed question. Data sharing 
revolution has taken shape in early 2000’s and was endorsed by prominent politicians in 
US. To date, the international Committee of Medical Journal Editors argues for an “ethical 
obligation to responsibly share data”, whereas the National Institute of health requires 
data sharing for investigator founded with more than a half-million dollars. In parallel, 
industry-, university- and non-profit-based sharing platform are rising 6. A very interesting 
example of sharing data potential has been observed with the SPRINT trial of which 
analysis was implemented and event corrected by external researchers 7,8.
The road map established for an affordable and sustainable CV health is bound together 
with big data development and data sharing. As further step to promote CV health 
globally, patient and public attitude to share health data for research should be 
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